Get started

Financials · FHTX

Foghorn Therapeutics Inc. (FHTX) financials

For the twelve months ended Sep 30, 2026, Foghorn Therapeutics Inc. reported $112.13M of revenue and $9.42M of net income.

Revenue, TTM
$112.13M
Revenue growth, YoY
+357.3%
Net income, TTM
$9.42M
Net margin
8.4%
Free cash flow, TTM
-$83.68M
EPS, diluted, TTM
$0.06
Cash
$80.30M
P/E
12.86
P/S
1.08
Market cap
$121.1M
Annual revenue$30.91M
FY2020FY2025
Annual net income-$74.28M
FY2019FY2025
Annual free cash flow-$86.15M
FY2019FY2025

FHTX revenue and earnings growth

FHTX revenueQ3 2026$83.54M

Quarter YoY
+924.7%
QoQ
+419.8%
FY YoY
+36.8%
5Y CAGR
+135.1%

FHTX revenue was $83.54M in fiscal Q3 2026 (ended Sep 30, 2026), up 924.7% from a year earlier and up 419.8% from the prior quarter. For the full fiscal 2025 it was $30.91M, up 36.8% from fiscal 2024. Compound annual growth was +135.1% over 5 years. It rose in 4 of the last 5 fiscal years.

FHTX net incomeQ3 2026$58.15M

FHTX net income was $58.15M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.85M a year earlier. For the full fiscal 2025 it was -$74.28M, compared with -$86.62M in fiscal 2024.

FHTX EPSQ3 2026$0.80

FHTX diluted EPS was $0.80 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.25 a year earlier. For the full fiscal 2025 it was -$1.18, compared with -$1.58 in fiscal 2024.

FHTX free cash flowQ3 2026-$18.25M

FHTX free cash flow was -$18.25M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$18.86M a year earlier. For the full fiscal 2025 it was -$86.15M, compared with -$101.31M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$30.91M$22.60M$34.16M$19.23M$1.32M$430.0K-
Research and development$85.47M$94.53M$109.69M$105.62M$80.33M$57.72M$44.36M
Selling, general and admin$27.55M$28.36M$32.37M$30.75M$21.73M$11.25M$6.72M
Operating income-$86.39M-$102.68M-$107.91M-$117.14M-$100.73M-$68.53M-$51.08M
Interest expense----$1.91M$979.0K$540.0K
Pre-tax income--$86.62M-$94.20M-$108.88M---
Income tax$0$0$4.23M$0-$0$0
Net income-$74.28M-$86.62M-$98.43M-$108.88M-$101.32M-$68.80M-$51.13M
EPS, basic-$1.18-$1.58-$2.34-$2.62-$2.73-$6.23-$12.20
EPS, diluted-$1.18-$1.58-$2.34-$2.62-$2.73-$6.23-$12.20
Diluted shares63.0M54.9M42.0M41.6M37.2M11.0M4.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$80.88M$57.16M$82.04M$53.92M$102.87M$94.53M$17.25M
Current assets$163.24M$249.60M$240.18M$351.40M$459.56M$190.69M$16.89M
Total assets$198.10M$283.98M$285.92M$404.88M$519.77M$255.59M$22.34M
Current liabilities$59.74M$66.99M$58.44M$55.20M$48.69M$18.85M$12.65M
Short-term debt-----$0$4.15M
Long-term debt----$0$19.65M$10.96M
Total debt----$0$19.65M$15.11M
Total liabilities$306.60M$329.51M$363.11M$404.77M$422.90M$109.41M$23.81M
Shareholders' equity-$108.50M-$45.53M-$77.19M$112.0K$96.87M$146.19M-$88.02M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$86.10M-$100.41M-$118.11M$193.61M-$50.25M-$31.29M-$46.34M
Capital expenditures$50.0K$906.0K$1.22M$1.21M$3.31M$16.18M$968.0K
Free cash flow-$86.15M-$101.31M-$119.33M$192.40M-$53.56M-$47.47M-$47.30M
Investing cash flow$112.04M-$29.90M$144.45M-$244.32M$36.17M-$108.91M-$964.0K
Financing cash flow$1.02M$105.43M$1.78M$1.76M$22.42M$217.47M$23.97M
Stock-based compensation$10.40M$11.89M$16.19M$14.34M$8.38M$2.96M$1.69M
Depreciation and amortization$3.33M$3.12M$3.45M$3.32M$3.23M$1.33M$693.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY36.8%-33.8%77.6%1357.8%206.7%--
Operating margin-279.5%-454.3%-315.9%-609.2%-7637.1%-15937.4%-
Net margin-240.3%-383.2%-288.2%-566.3%-7681.6%-16000.0%-
Free cash flow margin-278.7%-448.2%-349.4%1000.6%-4060.9%-11039.3%-
Return on equity----97216.1%-104.6%-47.1%-
Return on assets-37.5%-30.5%-34.4%-26.9%-19.5%-26.9%-228.8%
Current ratio2.733.734.116.379.4410.121.33
Debt to equity----0.000.13-

Source: XBRL data Foghorn Therapeutics Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

FHTX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
FHTX$112.13M+357.3%$9.42M8.4%$121.1M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

FHTX FAQ

8 questions
  • What is FHTX revenue?
    Foghorn Therapeutics Inc. (FHTX) reported $112.13M of revenue for the twelve months ended Sep 30, 2026. That is up 357.3% from the year before. Revenue for fiscal 2025 was $30.91M.
  • Is FHTX profitable?
    Yes. Foghorn Therapeutics Inc. earned $9.42M in net income for the twelve months ended Sep 30, 2026, a net margin of 8.4%.
  • How much cash and debt does FHTX have?
    Foghorn Therapeutics Inc. reported $80.30M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is FHTX revenue growing?
    Foghorn Therapeutics Inc.'s revenue changed +36.8% in fiscal 2025, to $30.91M. Its compound annual growth rate was +135.1% over 5 years.
  • What is FHTX free cash flow?
    Foghorn Therapeutics Inc. generated -$83.68M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$83.62M less capital expenditures.
  • What is FHTX earnings per share?
    Diluted earnings per share were $0.06 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did FHTX last report financial results?
    The latest statements here come from Foghorn Therapeutics Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.
  • Where does this FHTX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Foghorn Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.